Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

SetPoint Medical Receives Clinical Research Award at EULAR 2025 Congress

– RESET-RA is the first randomized, sham-controlled, double-blind trial to positively demonstrate the clinical potential of neuroimmune modulation for the treatment of rheumatoid arthritis (RA) –

– Oral presentation to highlight safety and efficacy results of the SetPoint System through 24 weeks–

SetPoint Medical, a clinical-stage healthcare company dedicated to people living with chronic autoimmune diseases, today announced that the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress selected its RESET-RA study as a recipient of the EULAR Abstract Award in the Clinical Research category. SetPoint was awarded for abstract OP0190 titled, “Neuroimmune Modulation for Treatment of Rheumatoid Arthritis in Adults with Inadequate Response or Intolerance to Biological or Targeted Synthetic DMARDs: Results at 12 and 24 weeks from a Randomized, Sham-Controlled, Double-Blind Study (RESET-RA Study).”

“We are honored to receive this prestigious award from EULAR, which recognizes the strength and promise of our clinical research using neuroimmune modulation for the treatment of rheumatoid arthritis,” said David Chernoff, M.D., Chief Medical Officer of SetPoint Medical. “This recognition reflects the dedication of our team to progressing the clinical development of the SetPoint System, and its potential to advance the care of individuals living with rheumatoid arthritis.”

EULAR bestows Abstract Awards to the highest-scoring abstracts that are submitted to its Annual European Congress in basic science or clinical research categories. Winners are selected by the EULAR Scientific Program Committee based on the quality of the abstracts' scientific content.

Dr. Chernoff will also present the 12- and 24-week results from the RESET-RA study in an oral abstract presentation on Thursday, June 12, 2025, at 10:30 - 10:40 AM CEST. John Tesser, MD, FACP, FACR, MACR of Arizona Arthritis & Rheumatology Associates in Phoenix, AZ, serves as the principal rheumatology investigator of the study.

Full EULAR 2025 abstract presentation details:

Title: Neuroimmune Modulation for Treatment of Rheumatoid Arthritis in Adults with Inadequate Response or Intolerance to Biological or Targeted Synthetic DMARDs: Results at 12 and 24 weeks from a Randomized, Sham-Controlled, Double-Blind Study (RESET-RA Study)

Clinical Abstract Session: Management strategies in Rheumatoid Arthritis

Location: Room A2

Date: Thursday, June 12, 2025

Time: 10:30 - 10:40 AM CEST

About SetPoint Medical

SetPoint Medical is a privately held clinical-stage healthcare company dedicated to treating people living with chronic autoimmune diseases. The company is developing a novel platform designed to stimulate the vagus nerve to activate neuroimmune pathways to produce a systemic anti-inflammatory and immune-restorative effect. SetPoint Medical’s platform technology is designed to offer patients and providers a treatment alternative for rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy. For more information, visit www.setpointmedical.com.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.